ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2019年04月08日 10時00分
Source:
Eisai
エーザイ、「チョコラBB(R)スパークリング キウイ&レモン味」新発売
朝からはじけるスパークリング!レモン75個分のビタミンC&カロリー50%オフ!
東京, 2019年04月08日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、炭酸入り栄養機能食品「チョコラBB(R)スパークリング キウイ&レモン味」を、4月9日(火)に全国で新発売します。
「チョコラBBスパークリング キウイ&レモン味」は、2011年の発売以来、働く女性を中心にご愛飲いただいている「チョコラBBスパークリング」の新フレーバー品です。レモン75個分のビタミンC 1500mgに加え、皮膚や粘膜の健康維持を助ける栄養素であるナイアシンの他、ビタミンB1、B6、Fe (鉄)といった、女性のキレイをサポートする5つの成分を配合した炭酸入りの栄養機能食品です。従来品の「グレープフルーツ&ピーチ味」と比べてカロリー50%オフを実現しました(24kcal)。
スッキリとした味わいの「キウイ&レモン味」を新たにラインナップに追加することで、生活者の皆様の「リフレッシュしたい」シーンに合わせ、2つのフレーバーから選んでお楽しみいただけるようになります。
当社は、チョコラBB(R)ブランド製品を通じて、多様化する女性のニーズにお応えするとともに、より多くの生活者の皆様の「キレイと元気」を応援してまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2019/news201924.html
概要:エーザイ株式会社
詳細はwww.eisai.co.jpをご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
NEC develops robot control technology using AI to achieve safe, efficient autonomous movement even at sites with many obstacles
Aug 21, 2025 10:39 JST
Hengdeli Announces 2025 Interim Results
Aug 20, 2025 20:52 JST
Honda Establishes New Subsidiary in India for Retail Financing Services
Aug 20, 2025 18:15 JST
Sharp Introduces Conversational AI Character "Poketomo"
Aug 20, 2025 16:22 JST
Collaborate with BNI, JCB Launch the 1st JCB Corporate Card in Indonesia
Aug 20, 2025 16:00 JST
NEC collaborates with WFP to strengthen cooperative development in Africa
Aug 20, 2025 15:53 JST
Hitachi High-Tech and NOF Metal Coatings use materials informatics to improve the efficiency and sophistication of research and development work
Aug 19, 2025 16:38 JST
NEC and ClimateAi Develop Conceptual Model to Promote Climate Change Adaptation in Agriculture
Aug 19, 2025 11:33 JST
Value Research Center to host The Valuism Conference 2025 on August 28-29 (Hybrid Format)
Aug 19, 2025 11:00 JST
Fujitsu signs new licensing agreement with Palantir
Aug 19, 2025 10:55 JST
The 35th Food Expo and concurrent fairs attract over 500,000 visits
Aug 18, 2025 21:07 JST
Team Mitsubishi Ralliart Triumphs at Asia Cross Country Rally 2025 with Chayapon Yotha's Overall Victory and Team Award
Aug 18, 2025 15:22 JST
UNFPA and NEC Collaborate to Build Beneficiary Information Management and e-Voucher System
Aug 18, 2025 14:38 JST
Anime Tokyo Station Surpasses 200,000 Visitors
Aug 18, 2025 11:00 JST
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
Aug 18, 2025 09:11 JST
TANAKA Holds Press Conference to Commemorate Its 140th Anniversary
Aug 15, 2025 03:00 JST
Mitsubishi Corporation to acquire shares in Copper World copper mine project in the US
Aug 14, 2025 12:05 JST
Team Mitsubishi Ralliart Conducts Shakedown Ahead of Asia Cross Country Rally 2025: Targeting First Overall Championship in Three Years
Aug 07, 2025 18:40 JST
Toyota to Establish New Vehicle Manufacturing Plant in Japan
Aug 07, 2025 18:31 JST
MHI Heat Pumps NZ Wins People's Choice Award for Third Year Running
Aug 07, 2025 17:32 JST
More Latest Release >>
Related Release
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
8/18/2025 9:11:00 AM JST
Revenue of LEQEMBI(R) (Preliminary Basis)
7/31/2025 6:27:00 PM JST
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
7/31/2025 9:30:00 AM JST
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
7/31/2025 9:20:00 AM JST
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
7/31/2025 9:10:00 AM JST
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
7/29/2025 9:01:00 AM JST
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
7/25/2025 1:31:00 PM JST
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
7/23/2025 10:07:00 AM JST
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025
7/22/2025 11:56:00 AM JST
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
7/16/2025 2:50:00 PM JST
More Press release >>